Edition:
United States

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

4.53EUR
20 Jul 2018
Change (% chg)

€-0.01 (-0.13%)
Prev Close
€4.54
Open
€4.54
Day's High
€4.63
Day's Low
€4.52
Volume
71,389
Avg. Vol
189,421
52-wk High
€11.40
52-wk Low
€4.33

Chart for

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 1.39
Market Cap(Mil.): €261.50
Shares Outstanding(Mil.): 57.60
Dividend: --
Yield (%): --

Financials

  IPH.PA Industry Sector
P/E (TTM): -- 214.53 33.05
EPS (TTM): -0.89 -- --
ROI: -25.05 -3.67 13.17
ROE: -56.22 -5.61 15.10

BRIEF-Innate Pharma Announces Promising Anti-Tumor Activity Of Monalizumab With Cetuximab In SCCHN

* PROMISING ANTI-TUMOR ACTIVITY OF MONALIZUMAB WITH CETUXIMAB IN SCCHN

Apr 17 2018

BRIEF-Reg-Innate Pharma Aacr 2018, New Preclinical Data Further Support Ongoing Programs

* REG-INNATE PHARMA : AACR 2018, NEW PRECLINICAL DATA FURTHER SUPPORT ONGOING PROGRAMS Source text for Eikon: Further company coverage:

Apr 17 2018

BRIEF-Innate Pharma Announces Its Partner Medimmune Expands Colorectal Cancer Patient Cohort In A Phase I Trial

* INNATE PHARMA SA - PARTNER MEDIMMUNE EXPANDS COLORECTAL CANCER PATIENT COHORT IN ONGOING PHASE I TRIAL EVALUATING MONALIZUMAB IN COMBINATION WITH IMFINZI® (DURVALUMAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 23 2018

BRIEF-Innate Pharma Expands mCRC Cohort In Phase I Trial Evaluating Monalizumab With Imfinzi

* REG-INNATE PHARMA : EXPANSION OF MCRC COHORT IN PHASE I TRIAL EVALUATING MONALIZUMAB WITH IMFINZI

Mar 23 2018

BRIEF-Innate Pharma FY Net Results Swings To Loss Of 48.4‍​ Million Euros

* FY REVENUE AND OTHER INCOME EUR 44.0‍​ MILLION VERSUS EUR 65.7 MILLION YEAR AGO

Mar 08 2018

BRIEF-Innate Pharma Appoints Jean-Yves Blay To Its Supervisory Board

* INNATE PHARMA SA - JEAN-YVES BLAY APPOINTED TO INNATE PHARMA SUPERVISORY BOARD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 31 2018

BRIEF-Innate Pharma And Medimmune Enter Clinical Trial Collaboration

* INNATE PHARMA AND MEDIMMUNE ENTER CLINICAL TRIAL COLLABORATION

Jan 30 2018

Earnings vs. Estimates